Affiliation:
1. HSBPVT’S, Shrigonda, Maharashtra, India
Abstract
The central nervous system disorders represent a worldwide public health problem. Neuro-degeneration is associated with many transitions in brain including synaptic disorder and neuro-cognition decline. It is shielded by a barrier which controls the entry of compounds into the brain known as blood brain barrier (BBB), there by regulating brain homeostasis. In achieving a therapeutic amount of drug to the proper site of action in the body and then maintaining the desired amount of drug concentration for a sufficient time interval to be clinically effective for treatment. Particularly, neurodegenerative diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are becoming further established in the elderly inhabitants of the society. These ailments usually encompass advanced degeneration & neuronal loss, rendering these disorders spread and difficult to treat. There are various types of pharmaceutical approaches to treat the neurological disorders. The drug loaded Nano-carriers are one of them. In this review, we will address the different applications of drug loaded Nano-carriers in the treatment of various neurological disorders. The Nano-carriers developed to enhance drug delivery across the BBB include micelles, exosomes, liposomes, nanotubes, nanoparticle, Nano emulsions, dendrimers, Nano gels, and quantum dots, etc. The recent developments in Nano-carriers’ implementation through size/charge optimization and surface modifications like PE Gylation, targeting delivery, and coating with surfactants have been discussed, and a detailed description of the Nano-scaled pharmaceutical delivery devices employed for the treatment of central nervous system disorders has also been defined. This review provides a brief overview of the variety of carriers employed for central nervous system drug and diagnostic probes delivery.
Publisher
IP Innovative Publication Pvt Ltd
Reference70 articles.
1. Kermani F, CNS Drugs and CNS Markets: A Strategic Guide to CNS Disorders, Markets and Therapies Available..
2. Baker SK, Chen ZL, Norris EH, Revenko AS, Macleod AR, Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.Proc Natl Acad Sci 2018;115(41):9687-96
3. Advances in the treatment of neurodegenerative disorders employing nanotechnology
4. Simonato M, Bennett J, Boulis NM, Goins MG, Gray SJ, Progress in gene therapy for neurological disorders.Nat Rev Neurol 2013;9(5):277-91
5. Nanoparticles for Brain Drug Delivery